

Bone Strength Formula



Discussion and Clinical Support

Calcium is the most plentiful mineral in the body, with almost all of it found in the bones and teeth. The remaining calcium is used for various bodily functions such as muscle contraction, blood clotting, and nerve communication. Along with phosphorus, magnesium, and other minerals, Calcium helps build and maintain bones and teeth.

surface area from which the minerals may be released from the organic matrix in the intestines. (1 - 7)

MCHA and Trace Minerals

MCHA and trace minerals aid in the synthesis and maintenance of bone tissue. (1 - 14)

Supplement Facts		
Serving Size: 4 Capsules Servings Per Container: 45		
	Amount Per Serving	% Daily Value
Calories	15	
Total Carbohydrate	<0.5 g	<1%*
Protein (from MCHA and AAC)	1.8 g (1,800 mg)	4%*
Vitamin C (from Magnesium Ascorbate)	200 mg	330%
Vitamin D-3 (as Cholecalciferol)	400 IU	100%
Vitamin B-1 (as Thiamine HCl)	100 mg	125%
Vitamin B-1 (from Thiamine HCl)	5 mg	300%
Calcium (from MCHA)	1.8 g (1,800 mg)	100%
Phosphorus (from MCHA)	450 mg	45%
Magnesium (from Magnesium Oxide and Ascorbate)	600 mg	150%
Zinc (from Zinc AAC)	10 mg	70%
Copper (from Copper AAC)	1 mg	50%
Manganese (from Manganese AAC)	3 mg	150%
MCHA (Microcrystalline Hydroxyapatite)	4.0 g (4,000 mg)	†
Glucosamine (Potassium Sulfate Complex)	300 mg	†
Horsefall (Equisetum arvense) (Aerial Parts)	100 mg	†
(Natural source of min. 5% water-soluble Silicates)		
Boron (from AAC)	3 mg	†

* Percent Daily Values are based on 2,000 calorie diet.
† Daily Value not established.

BENEFITS

SUPPORTS THE HEALTH AND STRENGTH OF THE BONES AND TEETH
COMPREHENSIVE BONE NUTRITION – SUPPLIES IMPORTANT MINERALS AND TRACE ELEMENTS
INCLUDES VITAMIN K, BORON & SOLUBLE SILICATES
MCHA-SOURCED CALCIUM AND PHOSPHORUS
MAY PROTECT COLORECTAL HEALTH

SUGGESTED USAGE

As a dietary supplement, take 4 capsules daily in 1-3 divided doses, preferably with meals.

CAUTIONS /INTERACTIONS

Calcium supplementation is contraindicated in those with hypercalcemia. Those who form calcium-containing kidney stones are generally advised not to take supplemental calcium.

Contains shellfish (crab, shrimp, lobster, crayfish) derivative.

Microcrystalline hydroxyapatite (MCHA) is the substance that gives bone its hardness. MCHA is an extremely bioavailable form of calcium and phosphorus, and provides a far superior absorption compared to traditional forms of calcium. Bone Strength™ Formula also contains magnesium (the fourth most abundant mineral in the body and essential to good health), trace minerals, and targeted vitamins such as C, D and K, which help to support healthy bone tissue.

Microcrystalline Hydroxyapatite (MCHA)

Microcrystalline hydroxyapatite (MCHA) is a natural compound that makes up the crystalline matrix of bone and teeth, and is the substance that gives them their rigidity. MCHA is a source of highly absorbable calcium and phosphorus, which are the major mineral components of bone. It produces a more prolonged calcium balance than do soluble calcium salts. It can cause the bone osteoblast cells to become receptive to its components and to build bone tissue. It has been proposed that the process is enhanced by the presence of the proteins, or the organic matrix, or that the microcrystalline structure provides a large

Vitamin K and Boron

Vitamin K is used to synthesize the protein osteocalcin, a protein unique to bone. Osteocalcin acts as a matrix on which calcium ions form crystals. Thus, K is essential for bone remodeling and repair. (15) Studies suggest that in post-menopausal women, boron plays a nutritional role in serum concentration of the estrogenic hormone 17B-estradiol. (16 - 17)

Calcium Supplementation for Preventing Colorectal Cancer

Calcium supplementation has been shown to decrease the risk of recurrence of colorectal adenomas in randomized trials. (18)

*THE STATEMENTS HEREIN HAVE NOT BEEN EVALUATED BY THE FDA. THESE PRODUCTS ARE NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE.

REFERENCES

1. Dent CE, Davies IJ. Calcium metabolism in bone disease: effects of treatment with microcrystalline calcium hydroxyapatite compound and dihydrotachysterol. *J R Soc Med.* 1980 Nov;73(11):780-5.
2. Pines A, Raafat H, Lynn AH, Whittington J. Clinical trial of microcrystalline hydroxyapatite compound (Ossopan) in the prevention of osteoporosis due to corticosteroid therapy. *Curr Med Res Opin.* 1984;8(10):734-42.
3. Stellon A, Davies A, Webb A, Williams R. Microcrystalline hydroxyapatite compound in prevention of bone loss in corticosteroid-treated patients with chronic active hepatitis. *Postgrad Med J.* 1985 Sep;61(719):791-6.
4. Castelo-Branco C, Pons F, Vicente JJ, Sanjuan A, Vanrell JA. Preventing postmenopausal bone loss with ossein-hydroxyapatite compounds. Results of a two-year, prospective trial. *J Reprod Med.* 1999 Jul;44(7):601-5.
5. Epstein O, Kato Y, Dick R, Sherlock S. Vitamin D, hydroxyapatite, and calcium gluconate in treatment of cortical bone thinning in postmenopausal women with primary biliary cirrhosis. *Am J Clin Nutr.* 1982 Sep;36(3):426-30.
6. Rügsegger P, et al., "Comparison of the treatment effect of ossein-hydroxyapatite compound and calcium carbonate in osteoporotic females," *Osteoporosis Int* 5, 1 (1995) 30-4.
7. Kohn R, "Historical review of microcrystalline hydroxyapatite compound," in *Osteoporosis, A Multi-disciplinary Problem*, edited by A. St. J. Dixon, et al. in *Royal Society of Medicine International Congress and Symposium Series No. 55* (1983) 265-267.
8. Di Daniele N, et al. Effect of supplementation of calcium and vitamin D on bone mineral density and bone mineral content in peri- and post-menopause women; a double-blind, randomized, controlled trial. *Pharmacol Res.* 2004 Dec;50(6):637-41.
9. Nielsen FH. Studies on the relationship between boron and magnesium which possibly affects the formation and maintenance of bones. *Magnes Trace Elem.* 1990;9(2):61-9.
10. Rude RK, Gruber HE. Magnesium deficiency and osteoporosis: animal and human observations. *J Nutr Biochem.* 2004 Dec;15(12):710-6.
11. Saltman PD, Strause LG. The role of trace minerals in osteoporosis. *J Am Coll Nutr.* 1993 Aug;12(4):384-9.
12. Schaafsma A, et al. Vitamin D(3) and vitamin K(1) supplementation of Dutch postmenopausal women with normal and low bone mineral densities: effects on serum 25-hydroxyvitamin D and carboxylated osteocalcin. *Eur J Clin Nutr.* 2000 Aug;54(8):626-31.
13. Strause L, Saltman P, Smith KT, Bracker M, Andon MB. Spinal bone loss in postmenopausal women supplemented with calcium and trace minerals. *J Nutr.* 1994 Jul;124(7):1060-4.
14. Volpe SL, Taper LJ, Meacham S. The relationship between boron and magnesium status and bone mineral density in the human: a review. *Magnes Res.* 1993 Sep;6(3):291-6.
15. Gallop PM, Lian JB, Hauschka PV. Carboxylated calcium-binding proteins and vitamin K. *N Engl J Med.* 1980 Jun 26;302(26):1460-6.
16. Meacham SL, Taper LJ, Volpe SL. Effect of boron supplementation on blood and urinary calcium, magnesium, and phosphorus, and urinary boron in athletic and sedentary women. *Am J Clin Nutr.* 1995 Feb;61(2):341-5.
17. Nielsen FH, Hunt CD, Mullen LM, Hunt JR. Effect of dietary boron on mineral, estrogen, and testosterone metabolism in postmenopausal women. *FASEB J.* 1987 Nov;1(5):394-7.
18. Grau MV, Baron JA, Sandler RS, Wallace K, Haile RW, Church TR, Beck GJ, Summers RW, Barry EL, Cole BF, Snover DC, Rothstein R, Mandel JS. Prolonged effect of calcium supplementation on risk of colorectal adenomas in a randomized trial. *J Natl Cancer Inst.* 2007 Jan 17;99(2):129-36.